Does the media refer more to RVMD or EXEL?

In the previous week, Revolution Medicines had 11 more articles in the media than Exelixis. MarketBeat recorded 14 mentions for Revolution Medicines and 3 mentions for Exelixis. Revolution Medicines' average media sentiment score of 0.58 beat Exelixis' score of 0.51 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EXEL or ALNY?

In the previous week, Alnylam Pharmaceuticals had 6 more articles in the media than Exelixis. MarketBeat recorded 9 mentions for Alnylam Pharmaceuticals and 3 mentions for Exelixis. Exelixis' average media sentiment score of 0.51 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, BIIB or EXEL?

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.33 $1.29B $5.65 39.45 Exelixis $2.32B 6.23 $782.57M $3.18 18.34

Is BIIB or EXEL more profitable?

Exelixis has a net margin of 35.33% compared to Biogen's net margin of 8.32%. Exelixis' return on equity of 42.17% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Exelixis 35.33% 42.17% 31.76%

Does the media refer more to BIIB or EXEL?

In the previous week, Biogen had 15 more articles in the media than Exelixis. MarketBeat recorded 18 mentions for Biogen and 3 mentions for Exelixis. Biogen's average media sentiment score of 0.82 beat Exelixis' score of 0.51 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 8 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, EXEL or ROIV?

Exelixis has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.23 $782.57M $3.18 18.34 Roivant Sciences $7.53M 3,407.35 -$299.77M -$0.53 N/A

Is EXEL or ROIV more profitable?

Exelixis has a net margin of 35.33% compared to Roivant Sciences' net margin of -3,534.96%. Exelixis' return on equity of 42.17% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Roivant Sciences -3,534.96% -22.94% -21.53%

Does the media favor EXEL or ROIV?

In the previous week, Roivant Sciences had 6 more articles in the media than Exelixis. MarketBeat recorded 9 mentions for Roivant Sciences and 3 mentions for Exelixis. Roivant Sciences' average media sentiment score of 0.58 beat Exelixis' score of 0.51 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, INSM or EXEL?

Exelixis has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $1.14B 20.20 -$1.28B -$4.11 N/A Exelixis $2.32B 6.23 $782.57M $3.18 18.34

Is INSM or EXEL more profitable?

Exelixis has a net margin of 35.33% compared to Insmed's net margin of -76.94%. Exelixis' return on equity of 42.17% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Exelixis 35.33% 42.17% 31.76%

Does the media refer more to INSM or EXEL?

In the previous week, Insmed had 7 more articles in the media than Exelixis. MarketBeat recorded 10 mentions for Insmed and 3 mentions for Exelixis. Exelixis' average media sentiment score of 0.51 beat Insmed's score of 0.23 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Exelixis 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Exelixis (EXEL) Competitors

$58.33 -0.52 (-0.88%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$58.32 -0.01 (-0.02%)

As of 08:00 AM Eastern

Compare

EXEL vs. RVMD, ALNY, BIIB, ROIV, and INSM

Should you buy Exelixis stock or one of its competitors? Exelixis's main competitors and comparable companies include Revolution Medicines (RVMD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Roivant Sciences (ROIV), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Exelixis compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Revolution Medicines had 11 more articles in the media than Exelixis. MarketBeat recorded 14 mentions for Revolution Medicines and 3 mentions for Exelixis. Revolution Medicines' average media sentiment score of 0.58 beat Exelixis' score of 0.51 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,699.49	-$1.13B	-$8.82	N/A
Exelixis	$2.32B	6.23	$782.57M	$3.18	18.34

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Exelixis has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Exelixis has a net margin of 35.33% compared to Revolution Medicines' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Exelixis	35.33%	42.17%	31.76%

Revolution Medicines presently has a consensus price target of $234.33, suggesting a potential upside of 17.24%. Exelixis has a consensus price target of $50.29, suggesting a potential downside of 13.79%. Given Revolution Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Revolution Medicines is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	2.96
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

Summary

Revolution Medicines beats Exelixis on 10 of the 17 factors compared between the two stocks.

How does Exelixis compare to Alnylam Pharmaceuticals?

Exelixis (NASDAQ:EXEL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Exelixis has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Exelixis has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Exelixis is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.23	$782.57M	$3.18	18.34
Alnylam Pharmaceuticals	$3.71B	8.07	$313.75M	$5.38	41.62

Exelixis has a net margin of 35.33% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Exelixis presently has a consensus price target of $50.29, suggesting a potential downside of 13.79%. Alnylam Pharmaceuticals has a consensus price target of $366.90, suggesting a potential upside of 63.84%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Alnylam Pharmaceuticals had 6 more articles in the media than Exelixis. MarketBeat recorded 9 mentions for Alnylam Pharmaceuticals and 3 mentions for Exelixis. Exelixis' average media sentiment score of 0.51 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats Exelixis on 11 of the 17 factors compared between the two stocks.

How does Exelixis compare to Biogen?

Biogen (NASDAQ:BIIB) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Exelixis has a net margin of 35.33% compared to Biogen's net margin of 8.32%. Exelixis' return on equity of 42.17% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Exelixis	35.33%	42.17%	31.76%

In the previous week, Biogen had 15 more articles in the media than Exelixis. MarketBeat recorded 18 mentions for Biogen and 3 mentions for Exelixis. Biogen's average media sentiment score of 0.82 beat Exelixis' score of 0.51 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	8 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen currently has a consensus target price of $230.14, suggesting a potential upside of 3.25%. Exelixis has a consensus target price of $50.29, suggesting a potential downside of 13.79%. Given Biogen's stronger consensus rating and higher probable upside, equities analysts clearly believe Biogen is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.33	$1.29B	$5.65	39.45
Exelixis	$2.32B	6.23	$782.57M	$3.18	18.34

87.9% of Biogen shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Biogen has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Summary

Biogen beats Exelixis on 10 of the 16 factors compared between the two stocks.

How does Exelixis compare to Roivant Sciences?

Exelixis (NASDAQ:EXEL) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Exelixis presently has a consensus target price of $50.29, indicating a potential downside of 13.79%. Roivant Sciences has a consensus target price of $45.64, indicating a potential upside of 28.44%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

85.3% of Exelixis shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Exelixis has a net margin of 35.33% compared to Roivant Sciences' net margin of -3,534.96%. Exelixis' return on equity of 42.17% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

In the previous week, Roivant Sciences had 6 more articles in the media than Exelixis. MarketBeat recorded 9 mentions for Roivant Sciences and 3 mentions for Exelixis. Roivant Sciences' average media sentiment score of 0.58 beat Exelixis' score of 0.51 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Exelixis has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.23	$782.57M	$3.18	18.34
Roivant Sciences	$7.53M	3,407.35	-$299.77M	-$0.53	N/A

Summary

Exelixis and Roivant Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Exelixis compare to Insmed?

Insmed (NASDAQ:INSM) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

In the previous week, Insmed had 7 more articles in the media than Exelixis. MarketBeat recorded 10 mentions for Insmed and 3 mentions for Exelixis. Exelixis' average media sentiment score of 0.51 beat Insmed's score of 0.23 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exelixis	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed currently has a consensus price target of $200.57, indicating a potential upside of 90.60%. Exelixis has a consensus price target of $50.29, indicating a potential downside of 13.79%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Insmed is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

Exelixis has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$1.14B	20.20	-$1.28B	-$4.11	N/A
Exelixis	$2.32B	6.23	$782.57M	$3.18	18.34

Insmed has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

85.3% of Exelixis shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Exelixis has a net margin of 35.33% compared to Insmed's net margin of -76.94%. Exelixis' return on equity of 42.17% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Exelixis	35.33%	42.17%	31.76%

Summary

Exelixis beats Insmed on 10 of the 16 factors compared between the two stocks.

Get Exelixis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXEL vs. The Competition

Export

Metric	Exelixis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.58B	$3.88B	$7.19B	$13.38B
Dividend Yield	N/A	3.65%	2.53%	17.39%
P/E Ratio	18.34	13.29	273.95	26.49
Price / Sales	6.23	1,243.13	641.28	108.98
Price / Cash	19.44	126.56	79.41	53.24
Price / Book	7.24	16.13	10.83	6.33
Net Income	$782.57M	-$22.65M	$3.50B	$381.96M
7 Day Performance	-0.14%	-4.14%	-2.08%	-0.41%
1 Month Performance	-1.15%	-12.14%	-7.07%	-4.85%
1 Year Performance	47.19%	13.75%	5.80%	1.42%

Exelixis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXEL Exelixis	2.9337 of 5 stars	$58.33 -0.9%	$50.29 -13.8%	+45.8%	$14.58B	$2.32B	18.34	1,077
RVMD Revolution Medicines	3.4849 of 5 stars	$204.48 +1.4%	$234.33 +14.6%	+329.1%	$43.83B	$11.58M	N/A	883
ALNY Alnylam Pharmaceuticals	4.2415 of 5 stars	$254.07 -0.5%	$367.20 +44.5%	-50.5%	$34.00B	$3.71B	47.22	2,500	Analyst Upgrade Insider Trade
BIIB Biogen	3.1138 of 5 stars	$227.07 -0.7%	$230.14 +1.4%	+44.7%	$33.55B	$9.89B	40.19	7,500	Trending News
ROIV Roivant Sciences	3.2401 of 5 stars	$36.50 -1.3%	$45.64 +25.0%	+118.5%	$26.36B	$8.26M	N/A	721	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXEL) was last updated on 10/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exelixis (EXEL) Competitors

EXEL vs. RVMD, ALNY, BIIB, ROIV, and INSM

How does Exelixis compare to Revolution Medicines?

Summary

How does Exelixis compare to Alnylam Pharmaceuticals?

Summary

How does Exelixis compare to Biogen?

Summary

How does Exelixis compare to Roivant Sciences?

Summary

How does Exelixis compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exelixis (EXEL) Competitors

EXEL vs. RVMD, ALNY, BIIB, ROIV, and INSM

How does Exelixis compare to Revolution Medicines?

Does the media refer more to RVMD or EXEL?

Which has higher valuation and earnings, RVMD or EXEL?

Which has more volatility and risk, RVMD or EXEL?

Do institutionals & insiders have more ownership in RVMD or EXEL?

Is RVMD or EXEL more profitable?

Do analysts rate RVMD or EXEL?

Summary

How does Exelixis compare to Alnylam Pharmaceuticals?

Which has more risk & volatility, EXEL or ALNY?

Which has better earnings & valuation, EXEL or ALNY?

Is EXEL or ALNY more profitable?

Do analysts recommend EXEL or ALNY?

Does the media prefer EXEL or ALNY?

Do insiders and institutionals hold more shares of EXEL or ALNY?

Summary

How does Exelixis compare to Biogen?

Is BIIB or EXEL more profitable?

Does the media refer more to BIIB or EXEL?

Do analysts prefer BIIB or EXEL?

Which has better earnings and valuation, BIIB or EXEL?

Do institutionals and insiders have more ownership in BIIB or EXEL?

Which has more volatility and risk, BIIB or EXEL?

Summary

How does Exelixis compare to Roivant Sciences?

Do analysts prefer EXEL or ROIV?

Do institutionals and insiders believe in EXEL or ROIV?

Is EXEL or ROIV more profitable?

Does the media favor EXEL or ROIV?

Which has more risk and volatility, EXEL or ROIV?

Which has higher valuation and earnings, EXEL or ROIV?

Summary

How does Exelixis compare to Insmed?

Does the media refer more to INSM or EXEL?

Do analysts prefer INSM or EXEL?

Which has preferable earnings & valuation, INSM or EXEL?

Which has more volatility and risk, INSM or EXEL?

Do insiders and institutionals have more ownership in INSM or EXEL?

Is INSM or EXEL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools